Copyright
©2014 Baishideng Publishing Group Inc.
World J Gastroenterol. Nov 21, 2014; 20(43): 16079-16094
Published online Nov 21, 2014. doi: 10.3748/wjg.v20.i43.16079
Published online Nov 21, 2014. doi: 10.3748/wjg.v20.i43.16079
Studied animals | Probiotic | Dose | Duration of treatment (wk) | Effects | Ref. |
C57BL/6J mice | Bifidobacterium breve B-3 | 109 CFU | 8 | ↓body weight, epididymal fat, serum cholesterol, glucose, insulin and HOMA index | [99] |
↑expression of FIAF, adiponectin | |||||
C57BL-6 mice | Bifidobacterium pseudocatenulatum CECT 7765 | 7 | ↓serum cholesterol, triglycerides, glucose, insulin resistance, leptin, IL-6, monocyte chemotactic protein-1, liver steatosis, adipose tissue | [100] | |
↑glucose tolerance | |||||
Improvement of immune system functionality | |||||
HFD-fed rats | Bifidobacterium longum | Improvement of HFD induced metabolic disorders trough ↓endotoxin levels and intestinal inflammation, ↑expression of Reg I genes | [101] | ||
HFD-rats, standard diets fed rats | Bifidobacterium adolescentis | 12 | ↓visceral fat, liver steatosis | [102] | |
↑insulin sensitivity | |||||
Sprague-Dawley rats | B. pseudocatenulatum SPM 1204, B. longum SPM 1205, and B. longum SPM 1207 | 108-109 CFU | 7 | ↓body and fat weights, serum cholesterol, triglycerides, glucose, leptin, AST, ALT and lipase levels | [103] |
Sprague-Dawley rats | Bifidobacteria L66-5, L75-4, M13-4 and FS31-12, originated from normal human intestines | 108 CFU | 6 | B. M13-4 strain ↑body weight | [104] |
B. L66-5 strain ↓body weight | |||||
All strains ↓serum and liver triglycerides, serum and liver cholesterol |
- Citation: Festi D, Schiumerini R, Eusebi LH, Marasco G, Taddia M, Colecchia A. Gut microbiota and metabolic syndrome. World J Gastroenterol 2014; 20(43): 16079-16094
- URL: https://www.wjgnet.com/1007-9327/full/v20/i43/16079.htm
- DOI: https://dx.doi.org/10.3748/wjg.v20.i43.16079